PT1453798E - (20s)-1alfa-hidroxi-2-metileno-19-nor-bishomopregnacalciferol e suas utilizações - Google Patents

(20s)-1alfa-hidroxi-2-metileno-19-nor-bishomopregnacalciferol e suas utilizações Download PDF

Info

Publication number
PT1453798E
PT1453798E PT02794233T PT02794233T PT1453798E PT 1453798 E PT1453798 E PT 1453798E PT 02794233 T PT02794233 T PT 02794233T PT 02794233 T PT02794233 T PT 02794233T PT 1453798 E PT1453798 E PT 1453798E
Authority
PT
Portugal
Prior art keywords
skin
compound
bishomopregnacalciferol
methylene
hydroxy
Prior art date
Application number
PT02794233T
Other languages
English (en)
Inventor
Hector F Deluca
Sumithra Gowlugari
Margaret Clagett-Dame
Lori A Plum
James B Thoden
Hazel M Holden
Pawel Grzywacz
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/078,204 external-priority patent/US6627622B2/en
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of PT1453798E publication Critical patent/PT1453798E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PT02794233T 2001-12-13 2002-12-12 (20s)-1alfa-hidroxi-2-metileno-19-nor-bishomopregnacalciferol e suas utilizações PT1453798E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34113801P 2001-12-13 2001-12-13
US10/078,204 US6627622B2 (en) 2002-02-18 2002-02-18 (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses

Publications (1)

Publication Number Publication Date
PT1453798E true PT1453798E (pt) 2009-01-23

Family

ID=26760229

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02794233T PT1453798E (pt) 2001-12-13 2002-12-12 (20s)-1alfa-hidroxi-2-metileno-19-nor-bishomopregnacalciferol e suas utilizações

Country Status (17)

Country Link
EP (1) EP1453798B1 (pt)
JP (1) JP4149928B2 (pt)
KR (1) KR100631457B1 (pt)
CN (1) CN1308303C (pt)
AT (1) ATE411283T1 (pt)
AU (1) AU2002359680B2 (pt)
CA (1) CA2468833C (pt)
CY (1) CY1108686T1 (pt)
DE (1) DE60229430D1 (pt)
DK (1) DK1453798T3 (pt)
ES (1) ES2315426T3 (pt)
HK (1) HK1077804A1 (pt)
MX (1) MXPA04005652A (pt)
NZ (1) NZ533424A (pt)
PT (1) PT1453798E (pt)
SI (1) SI1453798T1 (pt)
WO (1) WO2003051828A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704980B2 (en) * 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
US8404667B2 (en) * 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
DE602005021245D1 (de) * 2004-11-22 2010-06-24 Wisconsin Alumni Res Found 2-methylen-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and dessen verwendungen
US8604008B2 (en) 2004-11-22 2013-12-10 Wisconsin Alumni Research Foundation 2-methylene-19,21-dinor-1α-hydroxy-bishomopregnacalciferol
AU2005309818A1 (en) 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20R)-1-alpha-hydroxy-bishomopregnacalciferol
JP2008542201A (ja) * 2005-05-03 2008-11-27 ウイスコンシン アラムニ リサーチ ファンデーション １９，２６，２７−トリノル−１α，２５−ジヒドロキシビタミンＤ３化合物
EP2046737B1 (en) * 2006-04-06 2011-09-07 Wisconsin Alumni Research Foundation 2-methylene-1 alpha,25-dihydroxy-19,21-dinorvitamin d3 analogs and uses thereof
JP2009532458A (ja) * 2006-04-06 2009-09-10 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１α−ヒドロキシ−１９，２１−ジノルビタミンＤ３類縁体およびその使用
EP2001841B1 (en) * 2006-04-06 2012-06-13 Wisconsin Alumni Research Foundation 2-methylene-1 alpha-hydroxy-18,19,21-trinorvitamin d3 analogs and uses thereof
WO2008089093A2 (en) * 2007-01-12 2008-07-24 Quatrx Pharmaceuticals Company Efficient processes for preparing steroids and vitamin d derivatives with the unnatural configuration at c20 (20 alpha-methyl) from pregnenolone
MX2010009578A (es) 2008-03-06 2010-09-24 Wisconsin Alumni Res Found Metodos para incrementar el espesor epidermico de la piel mediante la administracion topica de un compuesto de vitamina d que contiene 19-nor.
AU2012271759B2 (en) * 2011-06-14 2017-02-02 Wisconsin Alumni Research Foundation 3-desoxy-2-methylene-19-nor-vitamin D analogs and their uses
US20130178449A1 (en) * 2011-07-18 2013-07-11 Wisconsin Alumni Research Foundation 2-Methylene-20(21)-Dehydro-19,24,25,26,27-Pentanor-Vitamin D Analogs
JP6114292B2 (ja) * 2011-10-21 2017-04-12 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−ビタミンｄ類似体およびそれらの使用
JP6072811B2 (ja) * 2011-10-21 2017-02-01 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−ビタミンｄ類似体およびそれらの使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58473B1 (en) * 1985-04-23 1993-09-22 Wisconsin Alumni Res Found Seco-sterol compounds effective in inducing the differentiation of malignant cells
JPH05238937A (ja) * 1992-03-09 1993-09-17 Wisconsin Alumni Res Found 細胞分化誘発薬剤
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6440953B1 (en) * 2000-09-08 2002-08-27 Wisconsin Alumni Research Foundation 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses

Also Published As

Publication number Publication date
MXPA04005652A (es) 2005-03-23
CN1620431A (zh) 2005-05-25
AU2002359680A1 (en) 2003-06-30
JP2005513066A (ja) 2005-05-12
KR100631457B1 (ko) 2006-10-11
ATE411283T1 (de) 2008-10-15
CA2468833C (en) 2009-09-08
DK1453798T3 (da) 2009-02-16
ES2315426T3 (es) 2009-04-01
NZ533424A (en) 2006-08-31
EP1453798B1 (en) 2008-10-15
AU2002359680B2 (en) 2007-10-18
SI1453798T1 (sl) 2009-04-30
DE60229430D1 (de) 2008-11-27
WO2003051828A2 (en) 2003-06-26
WO2003051828A3 (en) 2003-09-12
CN1308303C (zh) 2007-04-04
CA2468833A1 (en) 2003-06-26
JP4149928B2 (ja) 2008-09-17
CY1108686T1 (el) 2014-04-09
HK1077804A1 (en) 2006-02-24
KR20040063949A (ko) 2004-07-14
EP1453798A2 (en) 2004-09-08

Similar Documents

Publication Publication Date Title
HK1077804A1 (en) (20S)-1Alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
HK1077508A1 (en) 1-Alpha-hydroxy-2-methylene-19-nor-pregnacal ciferol and its uses
IL154699A0 (en) 1alpha-HYDROXY-2-METHYLENE-19-NOR-HOMOPREGNACALCIFEROL AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
ATE415164T1 (de) (20s)-1alpha-hydroxy-2alpha-methyl und 2beta- methyl-19-nor vitamin d3 und ihre verwendung
WO2006057884A3 (en) 2α-METHYL AND 2ß-METHYL ANALOGS OF 19,26,27-TRINOR-(20S)-1α-HYDROXYVITAMIN D3 AND THEIR USES
WO2006057899A3 (en) 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses
WO2006057901A3 (en) 2-METHYLENE-19-NOR-1α-HYDROXY-17-ENE-HOMOPREGNACALCIFEROL AND ITS USES
WO2006057886A3 (en) 2-METHYLENE-19,26,27-TRINOR-(20S)-1α-HYDROXYVITAMIN D3 AND ITS USES
ATE472528T1 (de) 2-methylen-18,19-dinor-1alfa-hydroxy- homopregnacalciferol und dessen verwendungen
MX2010007205A (es) Analogos de vitamina d, 2-metilen-20-metil-19, 24, 25, 26, 27-pentanor.
MX2009002944A (es) Analogos de 2-metilen-(20s,25s)-19,27-dinor-(22e)-vitamina d.
WO2006057902A3 (en) 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses
WO2009086439A3 (en) 2-methylene-(20s,25s)-19,26-dinor-vitamin d analogs